CL2013000667A1 - Celulas de sangre total sin plasma; dispositivo para la utilización en un metodo de tratamiento de trasntornos del colesterol; sistema que comprende composicion que consiste en celulas de sangre total sin plasma y dispositivo; uso de plasmaféresis en dos o mas ciclos. - Google Patents

Celulas de sangre total sin plasma; dispositivo para la utilización en un metodo de tratamiento de trasntornos del colesterol; sistema que comprende composicion que consiste en celulas de sangre total sin plasma y dispositivo; uso de plasmaféresis en dos o mas ciclos.

Info

Publication number
CL2013000667A1
CL2013000667A1 CL2013000667A CL2013000667A CL2013000667A1 CL 2013000667 A1 CL2013000667 A1 CL 2013000667A1 CL 2013000667 A CL2013000667 A CL 2013000667A CL 2013000667 A CL2013000667 A CL 2013000667A CL 2013000667 A1 CL2013000667 A1 CL 2013000667A1
Authority
CL
Chile
Prior art keywords
plasma
blood cells
plasmapheresis
cycles
composition consisting
Prior art date
Application number
CL2013000667A
Other languages
English (en)
Inventor
Lucas Victor Grifols
Roura Victor Grifols
Original Assignee
Grifols Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols Sa filed Critical Grifols Sa
Publication of CL2013000667A1 publication Critical patent/CL2013000667A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3496—Plasmapheresis; Leucopheresis; Lymphopheresis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3621—Extra-corporeal blood circuits
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3693—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits using separation based on different densities of components, e.g. centrifuging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/38—Removing constituents from donor blood and storing or returning remainder to body, e.g. for transfusion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/75—General characteristics of the apparatus with filters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/12—Blood circulatory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • External Artificial Organs (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Células de sangre total sin plasma; dispositivo para la utilización en un método de tratamiento de trastornos del colesterol; sistema que comprende composición que consiste en células de sangre total sin plasma y dispositivo; uso de plasmaféresis en dos o más ciclos.
CL2013000667A 2012-03-12 2013-03-11 Celulas de sangre total sin plasma; dispositivo para la utilización en un metodo de tratamiento de trasntornos del colesterol; sistema que comprende composicion que consiste en celulas de sangre total sin plasma y dispositivo; uso de plasmaféresis en dos o mas ciclos. CL2013000667A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13/418,123 US10624924B2 (en) 2012-03-12 2012-03-12 Method and device for treating blood cholesterol disorders

Publications (1)

Publication Number Publication Date
CL2013000667A1 true CL2013000667A1 (es) 2013-07-12

Family

ID=47891413

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013000667A CL2013000667A1 (es) 2012-03-12 2013-03-11 Celulas de sangre total sin plasma; dispositivo para la utilización en un metodo de tratamiento de trasntornos del colesterol; sistema que comprende composicion que consiste en celulas de sangre total sin plasma y dispositivo; uso de plasmaféresis en dos o mas ciclos.

Country Status (24)

Country Link
US (1) US10624924B2 (es)
EP (1) EP2638918B1 (es)
JP (1) JP6218401B2 (es)
KR (2) KR20130105452A (es)
CN (2) CN107754038A (es)
AR (1) AR090295A1 (es)
AU (1) AU2013201550B2 (es)
BR (1) BR102013005877B1 (es)
CA (1) CA2809012C (es)
CL (1) CL2013000667A1 (es)
ES (1) ES2598241T3 (es)
HK (1) HK1185791A1 (es)
HU (1) HUE029681T2 (es)
IL (1) IL225129A (es)
MX (1) MX344112B (es)
MY (1) MY169320A (es)
NZ (1) NZ608133A (es)
PL (1) PL2638918T3 (es)
PT (1) PT2638918T (es)
RU (1) RU2625774C2 (es)
SG (1) SG193729A1 (es)
TW (1) TWI554275B (es)
UY (1) UY34667A (es)
ZA (1) ZA201301815B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10624924B2 (en) 2012-03-12 2020-04-21 Grifols, S.A. Method and device for treating blood cholesterol disorders
AU2015201496B2 (en) * 2014-06-03 2019-10-31 Grifols Worldwide Operations Limited Use of plasmapheresis to treat blood pressure disorders

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4374731A (en) 1980-03-06 1983-02-22 Baxter Travenol Laboratories, Inc. Method and apparatus for obtaining a desired rate of plasma collection from a membrane plasmapheresis filter
US4350156A (en) 1980-05-29 1982-09-21 Japan Foundation For Artificial Organs Method and apparatus for on-line filtration removal of macromolecules from a physiological fluid
US4540401A (en) * 1983-02-22 1985-09-10 Applied Immune Sciences, Inc. In vivo therapeutic apheresis using lipid vesicles
EP0188451B1 (en) 1984-06-29 1991-12-11 BAXTER INTERNATIONAL INC. (a Delaware corporation) Blood extraction and reinfusion flow control system and method
US5258149A (en) 1990-11-27 1993-11-02 W. R. Grace & Co.-Conn. Process of making a membrane for high efficiency removal of low density lipoprotein-cholesterol from whole blood
CA2095424A1 (en) 1992-05-14 1993-11-15 Marc Ellous Parham Microporous polysulfone support suitable for removal of low density lipoprotein-cholesterol
JPH06254152A (ja) * 1993-03-03 1994-09-13 Terumo Corp 血漿交換装置
JPH0788179A (ja) * 1993-09-22 1995-04-04 Terumo Corp 血漿交換装置
RU2113240C1 (ru) 1995-05-05 1998-06-20 Акционерное общество закрытого типа "Оптика" Способ мембранного плазмафереза по одноигольной схеме под действием силы тяжести и устройство для его осуществления
AU5874896A (en) 1995-05-26 1996-12-11 Diacrin, Inc. Porcine hepatocytes for use in treatment of disorders characterized by insufficient liver function
AU708340B2 (en) 1995-10-23 1999-08-05 Hemasure, Inc. Extra-lumenal crossflow plasmapheresis devices
FR2747591B1 (fr) 1996-04-19 1998-05-22 Hospal Ind Appareil medical pour le traitement extracorporel du sang ou du plasma et procedes de fabrication de cet appareil
JP2000512635A (ja) * 1996-06-07 2000-09-26 イーライ リリー アンド カンパニー Ｏｂタンパク質を結合するタンパク質
US6627151B1 (en) 1997-06-13 2003-09-30 Helmut Borberg Method for treatment diseases associated with a deterioration of the macrocirculation, microcirculation and organ perfusion
RU2153168C2 (ru) * 1997-11-25 2000-07-20 Научно-исследовательский институт кардиологии Способ определения показаний к проведению плазмафереза при лечении стенокардии
DE19821534C1 (de) 1998-05-14 1999-08-19 Braun Melsungen Ag Blutreinigungsmaschine
US6551266B1 (en) * 1998-12-29 2003-04-22 Occulogix Corporation Rheological treatment methods and related apheresis systems
CA2368809C (en) 1999-04-30 2005-10-25 John J. Bissler Hemofiltration system
RU2195321C2 (ru) 2000-11-16 2002-12-27 Государственный научно-клинический центр охраны здоровья шахтеров Способ лечения церебрального атеросклероза
US6991727B2 (en) 2001-06-25 2006-01-31 Lipid Sciences, Inc. Hollow fiber contactor systems for removal of lipids from fluids
US6982038B2 (en) * 2002-06-14 2006-01-03 Medtronic, Inc. Centrifuge system utilizing disposable components and automated processing of blood to collect platelet rich plasma
AU2003251567A1 (en) 2002-06-19 2004-01-06 The Board Of Regents Of The University Of Texas System Dialysis system for treatment of vulnerable patients and methods of use
AU2003303198A1 (en) 2002-12-19 2004-07-14 New York University Method for treating amyloid disease
ES2547547T3 (es) * 2003-07-03 2015-10-07 Hdl Therapeutics, Inc. Enriquecimiento de lipoproteínas de alta densidad pre-beta
US7393826B2 (en) 2003-07-03 2008-07-01 Lipid Sciences, Inc. Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
US20050051497A1 (en) 2003-07-31 2005-03-10 Latino Joseph S. Viral inactivation using ozone
US20100316730A1 (en) * 2003-07-31 2010-12-16 Latino Joseph S Treatment of cardiovascular diseases with ozone
US8038638B2 (en) 2004-02-23 2011-10-18 Hemolife Medical, Inc. Plasma detoxification and volume control system and methods of use
DE102004054747A1 (de) 2004-11-12 2006-05-24 Fresenius Medical Care Deutschland Gmbh Verfahren und Vorrichtung zur Abreicherung wenigstens einer Komponente eines fluiden Mediums
JP2009502446A (ja) 2005-08-05 2009-01-29 ナショナル・クオリティ・ケア・インコーポレイテッド デュアルチャネルポンプカートリッジ及び透析用のポンプ
RU2310478C1 (ru) 2006-05-03 2007-11-20 Александр Георгиевич Рожков Способ лечения атеросклероза
GB0621452D0 (en) 2006-10-27 2006-12-06 Ucl Business Plc Therapy for liver disease
CN100500229C (zh) 2006-12-29 2009-06-17 上海达华医疗器械有限公司 一种多功能体外血液治疗仪
FR2911417B1 (fr) 2007-01-17 2009-02-27 Gambro Lundia Ab Suivi de l'acces vasculaire d'un patient soumis a des seances successives de traitement extracorporel de sang
US20120165685A1 (en) 2010-12-22 2012-06-28 Weasler Marc N Plasmapheresis donor display and method of use
CN201006071Y (zh) 2007-02-13 2008-01-16 沈建华 一种智能输液泵
US8409441B2 (en) 2007-02-27 2013-04-02 Deka Products Limited Partnership Blood treatment systems and methods
KR20110103428A (ko) 2008-12-19 2011-09-20 안테라 파마슈티칼즈, 인크. 분비성 포스포리파제 Ａ２ （ｓＰＬＡ２） 억제제 또는 ｓＰＬＡ２ 억제제 조합 치료요법을 이용한 주요 유해 심장 사건 및 급성 관상동맥 증후군의 치료
WO2011015380A1 (en) 2009-08-05 2011-02-10 Celltrend Gmbh Method for prognosis of pulmonary arterial hypertension by detecting anti-par2-antibodies
EP2485983B1 (en) 2009-10-08 2017-05-03 Otsuka Pharmaceutical Co., Ltd. An immunoactivation blood perfusion filter for the treatment of malignant tumors
WO2011080191A1 (en) 2009-12-28 2011-07-07 Gambro Lundia Ab Monitoring blood pressure
US10052345B2 (en) 2010-10-19 2018-08-21 University Of Miami Assays, methods and kits for predicting renal disease and personalized treatment strategies
WO2012109282A2 (en) 2011-02-07 2012-08-16 Agamin Pharmaceuticals, Llc Methods and systems for treating or preventing pregnancy-related hypertensive disorders
US10624924B2 (en) 2012-03-12 2020-04-21 Grifols, S.A. Method and device for treating blood cholesterol disorders

Also Published As

Publication number Publication date
MY169320A (en) 2019-03-21
HK1185791A1 (zh) 2014-02-28
US20130236559A1 (en) 2013-09-12
RU2625774C2 (ru) 2017-07-18
PL2638918T3 (pl) 2017-01-31
KR20130105452A (ko) 2013-09-25
BR102013005877A2 (pt) 2017-07-11
TW201340973A (zh) 2013-10-16
BR102013005877B1 (pt) 2021-10-26
ZA201301815B (en) 2013-11-27
US10624924B2 (en) 2020-04-21
MX2013002681A (es) 2013-09-12
SG193729A1 (en) 2013-10-30
CA2809012A1 (en) 2013-09-12
IL225129A0 (en) 2013-06-27
EP2638918A1 (en) 2013-09-18
AR090295A1 (es) 2014-11-05
AU2013201550B2 (en) 2015-07-02
AU2013201550A1 (en) 2013-09-26
CA2809012C (en) 2020-04-14
NZ608133A (en) 2014-09-26
IL225129A (en) 2017-02-28
ES2598241T3 (es) 2017-01-26
CN103301520A (zh) 2013-09-18
PT2638918T (pt) 2016-10-24
UY34667A (es) 2013-10-31
KR20180074646A (ko) 2018-07-03
KR101908899B1 (ko) 2018-10-16
JP2013188475A (ja) 2013-09-26
HUE029681T2 (en) 2017-02-28
JP6218401B2 (ja) 2017-10-25
MX344112B (es) 2016-11-30
EP2638918B1 (en) 2016-08-31
CN107754038A (zh) 2018-03-06
TWI554275B (zh) 2016-10-21
RU2013110503A (ru) 2014-09-20

Similar Documents

Publication Publication Date Title
CY1124729T1 (el) Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου
BR112016008694A2 (pt) Métodos de previsão da reação de pacientes com asma, de previsão da capacidade de reação de pacientes com asma, de identificação de pacientes com asma, de tratamento de pacientes portadores de asma e de tratamento de asma, uso de um kit e kit
BR112017019738A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
BR112014026990A2 (pt) anticorpo , ácido nucleico , vetores , célula hospedeira , composição farmacêutica , uso de um anticorpo e método para o tratamento de um paciente com necessidade de terapia.
CL2015000699A1 (es) Métodos para tratamiento de cáncer.
CL2015000092A1 (es) Oligonucleótidos quiralmente controlados, composición que los comprende; método de elaboración: y uso para tratar cáncer.
CL2014002549A1 (es) Anticuerpos anti-lgr5 e inmunoconjugados; formulacion farmaceutica que los contiene; metodo de tratamiento en los que se administra anticuerpos anti-lgr5 e inmunoconjugados.
CL2016001076A1 (es) (aza) piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinolosis.
BR112017005598A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
PT2848097T (pt) Dispositivo para o tratamento de plasma de superfícies humanas, animais ou de plantas, em particular da pele ou de áreas de membrana mucosa
DK3311827T3 (da) Nanopartikler, fremgangsmåde til fremstilling og anvendelse deraf som bærere for amfipatiske eller hydrofobe molekyler inden for det medicinske område, inklusiv cancerbehandling, samt fødevarerelaterede forbindelser
BR112014000796A2 (pt) localizadores esternais e sistemas e métodos associados
BR112015023203A8 (pt) métodos para tratamento de câncer, método para aumentar a eficiência de um tratamento de câncer, método para retardar e/ou prevenir o desenvolvimento de câncer, método para tratar um indivíduo com câncer, método para aumentar a sensibilidade para um agente de terapia para câncer, método para estender um período de sensibilidade e método para estender a duração da resposta para uma terapia para câncer.
CL2015002807A1 (es) Terapia de combinación
BR112013031210A2 (pt) processo para o tratamento das fibras queratínicas, kit e uso de um dispositivo
DK2815769T3 (da) Fam19a5 til anvendelse i diagnosticering og behandling af skader på centralnervesystemet
AR092899A1 (es) Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion
BR112017004059A2 (pt) dispositivo de hemoperfusão utilizável
TR201904980T4 (tr) Bir B-Raf inhibitörü, bir EGFR inhibitörü ve isteğe bağlı olarak bir PI3K-alfa inhibitörü içeren farmasötik kombinasyonlar.
BR112015023439A2 (pt) combinação de tratamentos de câncer utilizando micrornas e inibidores egfr-tki
BR112015004260A2 (pt) dispositivo e processo para o tratamento de tecido biológico mediante o uso de um plasma de baixa pressão
BR112015027477A8 (pt) bolus, seus usos, e kit
CL2015001085A1 (es) Formulacion de liberación prolongada que comprende oprozomib y ademas uno o mas polimeros farmaceuticamente aceptables; metodo de preparacion de la formulacion; metodo para tratar cancer.
FR2997019B1 (fr) Dispositif, appareil et procede de traitement cosmetique par la lumiere
EP2774635A4 (en) SEPARATION MEMBRANE FOR BLOOD TREATMENT, AND BLOOD TREATMENT APPARATUS WITH SUCH AN INTEGRATED MEMBRANE